Ramipril

DRUG INFORMATION

  ADULT
    - DOSAGE AND ADMINISTRATIO Hypertension: Initial dose is 2.5 mg to 20 mg once daily.
      Source: US FDA label for ramipril (Ramipril), section 'dosage and administration',
      retrieved 2026-08-29
    - The usual maintenance dose following titration is 2.5 mg to 20 mg daily as a
      single dose or equally divided doses ( 2.1 ).
      Source: US FDA label for ramipril (Ramipril), section 'dosage and administration',
      retrieved 2026-08-29
    - Reduction in the risk of myocardial infarction, stroke, or death from
      cardiovascular causes: 2.5 mg once daily for 1 week, 5 mg once daily for 3 weeks,
      and increased as tolerated to a maintenance dose of 10 mg once daily (2.2).
      Source: US FDA label for ramipril (Ramipril), section 'dosage and administration',
      retrieved 2026-08-29

  CHILD
    - Neonates with a history of in utero exposure to ramipril If oliguria or
      hypotension occurs, direct attention toward support of blood pressure and renal
      perfusion. Exchange transfusions or dialysis may be required as a means of
      reversing hypotension and/or substituting for disordered renal function.
      Source: US FDA label for ramipril (Ramipril), section 'pediatric use', retrieved
      2026-08-29

  RENAL IMPAIRMENT
    - Usual regimens of therapy with ramipril capsules may be followed in patients with
      estimated creatinine clearance >40 mL/min.
      Source: US FDA label for ramipril (Ramipril), section 'dosage and administration',
      retrieved 2026-08-29
    - Hypertension For patients with hypertension and renal impairment, the recommended
      initial dose is 1.25 mg ramipril capsules once daily.
      Source: US FDA label for ramipril (Ramipril), section 'dosage and administration',
      retrieved 2026-08-29
    - Heart Failure Post-Myocardial Infarction For patients with heart failure and renal
      impairment, the recommended initial dose is 1.25 mg ramipril capsules once daily.
      Source: US FDA label for ramipril (Ramipril), section 'dosage and administration',
      retrieved 2026-08-29

  HEPATIC IMPAIRMENT
    - No liver-impairment dose in this label. Not a statement that none is needed.
      Source: Read and found silent: the US FDA label for ramipril (Ramipril), retrieved
      2026-08-29

  PREGNANCY
    - Pregnancy Category D Use of drugs that act on the renin-angiotensin system during
      the second and third trimesters of pregnancy reduces fetal renal function and
      increases fetal and neonatal morbidity and death.
      Source: US FDA label for ramipril (Ramipril), section 'pregnancy', retrieved
      2026-08-29
    - Resulting oligohydramnios can be associated with fetal lung hypoplasia and
      skeletal deformations.
      Source: US FDA label for ramipril (Ramipril), section 'pregnancy', retrieved
      2026-08-29
    - Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension,
      renal failure, and death.
      Source: US FDA label for ramipril (Ramipril), section 'pregnancy', retrieved
      2026-08-29

  BREASTFEEDING
    - Ingestion of a single 10 mg oral dose of ramipril resulted in undetectable amounts
      of ramipril and its metabolites in breast milk.
      Source: US FDA label for ramipril (Ramipril), section 'nursing mothers', retrieved
      2026-08-29
    - However, because multiple doses may produce low milk concentrations that are not
      predictable from a single dose, do not use ramipril in nursing mothers.
      Source: US FDA label for ramipril (Ramipril), section 'nursing mothers', retrieved
      2026-08-29
    - Nursing mothers: Ramipril use is not recommended in nursing mothers ( 8.3 ). 8.1
      Pregnancy Pregnancy Category D Use of drugs that act on the renin-angiotensin
      system during the second and third trimesters of pregnancy reduces fetal renal
      function and increases fetal and neonatal morbidity and death.
      Source: US FDA label for ramipril (Ramipril), section 'use in specific
      populations', retrieved 2026-08-29